Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Stefano Fontana is active.

Publication


Featured researches published by Stefano Fontana.


Journal of Immunology | 2014

Oxypurinol Directly and Immediately Activates the Drug-Specific T Cells via the Preferential Use of HLA-B*58:01

James Jin Sup Yun; Maria J Marcaida; Klara Eriksson; Heidi Jamin; Stefano Fontana; Werner J. Pichler; Daniel Yerly

Allopurinol (ALP) hypersensitivity is a major cause of severe cutaneous adverse reactions and is strongly associated with the HLA-B*58:01 allele. However, it can occur in the absence of this allele with identical clinical manifestations. The immune mechanism of ALP-induced severe cutaneous adverse reactions is poorly understood, and the T cell–reactivity pattern in patients with or without the HLA-B*58:01 allele is not known. To understand the interactions among the drug, HLA, and TCR, we generated T cell lines that react to ALP or its metabolite oxypurinol (OXP) from HLA-B*58:01+ and HLA-B*58:01− donors and assessed their reactivity. ALP/OXP-specific T cells reacted immediately to the addition of the drugs and bypassed intracellular Ag processing, which is consistent with the “pharmacological interaction with immune receptors” (p-i) concept. This direct activation occurred regardless of HLA-B*58:01 status. Although most OXP-specific T cells from HLA-B*58:01+ donors were restricted by the HLA-B*58:01 molecule for drug recognition, ALP-specific T cells also were restricted to other MHC class I molecules. This can be explained by in silico docking data that suggest that OXP binds to the peptide-binding groove of HLA-B*58:01 with higher affinity. The ensuing T cell responses elicited by ALP or OXP were not limited to particular TCR Vβ repertoires. We conclude that the drug-specific T cells are activated by OXP bound to HLA-B*58:01 through the p-i mechanism.


Clinical & Experimental Allergy | 2013

Allopurinol hypersensitivity is primarily mediated by dose‐dependent oxypurinol‐specific T cell response

J. Yun; J. Mattsson; K. Schnyder; Stefano Fontana; Carlo R. Largiadèr; Werner J. Pichler; Daniel Yerly

Allopurinol is a main cause of severe cutaneous adverse reactions (SCAR). How allopurinol induces hypersensitivity remains unknown. Pre‐disposing factors are the presence of the HLA‐B*58:01 allele, renal failure and possibly the dose taken.


Journal of Immunology | 2013

HLA Haplotype Determines Hapten or p-i T Cell Reactivity to Flucloxacillin

Natascha Wuillemin; Jacqueline Adam; Stefano Fontana; Stephan Krähenbühl; Werner J. Pichler; Daniel Yerly

Drug-induced liver injury (DILI) is a main cause of drug withdrawal. A particularly interesting example is flucloxacillin (FLUX)-DILI, which is associated with the HLA-B*57:01 allele. At present, the mechanism of FLUX-DILI is not understood, but the HLA association suggests a role for activated T cells in the pathomechanism of liver damage. To understand the interaction among FLUX, HLA molecules, and T cells, we generated FLUX-reacting T cells from FLUX-naive HLA-B*57:01+ and HLA-B*57:01− healthy donors and investigated the mechanism of T cell stimulation. We found that FLUX stimulates CD8+ T cells in two distinct manners. On one hand, FLUX was stably presented on various HLA molecules, resistant to extensive washing and dependent on proteasomal processing, suggesting a hapten mechanism. On the other hand, in HLA-B*57:01+ individuals, we observed a pharmacological interaction with immune receptors (p-i)–based T cell reactivity. FLUX was presented in a labile manner that was further characterized by independence of proteasomal processing and immediate T cell clone activation upon stimulation with FLUX in solution. This p-i–based T cell stimulation was restricted to the HLA-B*57:01 allele. We conclude that the presence of HLA-B*57:01 drives CD8+ T cell responses to the penicillin-derivative FLUX toward nonhapten mechanism.


European Journal of Immunology | 2012

Avidity determines T-cell reactivity in abacavir hypersensitivity.

Jacqueline Adam; Klara Eriksson; Benno Schnyder; Stefano Fontana; Werner J. Pichler; Daniel Yerly

The antiretroviral drug abacavir (abc) elicits severe drug hypersensitivity reactions in HLA‐B*5701+ individuals. To understand the abc‐specific activation of CD8+ T cells, we generated abc‐specific T‐cell clones (abc‐TCCs). Abc reactivity could not be linked to the metabolism and/or processing of the drug, since abc metabolizing enzymes were not expressed in immune cells and inhibition of the proteasome in APCs did not affect TCC reactivity. Ca2+ influx assays revealed different reactivity patterns of abc‐TCCs. While all TCCs reacted to abc presented on HLA‐B*5701 molecules, a minority also reacted immediately to abc in solution. Titration experiments showed that the ability to react immediately to abc correlated significantly with the TCR avidity of the T cells. Modifications of soluble abc concentrations revealed that the reactivity patterns of abc‐TCCs were not fixed but dynamic. When TCCs with an intermediate TCR avidity were stimulated with increasing abc concentrations, they showed an accelerated activation kinetic. Thus, they reacted immediately to the drug, similar to the reaction of TCCs of high avidity. The observed immediate activation and the noninvolvement of the proteasome suggest that, in contrast to haptens, abc‐specific T‐cell stimulation does not require the formation of covalent bonds to produce a neo‐antigenic determinant.


Transfusion | 2005

Oxaliplatin‐induced immune pancytopenia

Behrouz Mansouri Taleghani; Stefano Fontana; Oliver Meyer; Norbert Ahrens; Urban Novak; Markus Borner; Abdulgabar Salama

BACKGROUND: Oxaliplatin, a third‐generation platinum compound, has been implicated in isolated cases of immune hemolytic anemia and/or immune thrombocytopenia. The first case of severe immune pancytopenia related to oxaliplatin is described.


Transfusion | 2009

Transfusion efficacy of ABO major‐mismatched platelets (PLTs) in children is inferior to that of ABO‐identical PLTs

Friedgard Julmy; Roland A. Ammann; Behrouz Mansouri Taleghani; Stefano Fontana; Andreas Hirt; Kurt Leibundgut

BACKGROUND: ABO major compatibility is essential in transfusions of red blood cells but is not requisite in PLT transfusions. In adults there is some evidence that transfusion efficacy of ABO blood group–identical platelets (PLTs) is superior to major‐mismatched PLTs. However, in children this question has not been investigated for more than 30 years.


PLOS ONE | 2014

Abacavir Induced T Cell Reactivity from Drug Naïve Individuals Shares Features of Allo-Immune Responses

Jacqueline Adam; Natascha Andrea Wuillemin; Stephan Watkins; Heidi Jamin; Klara Eriksson; Peter M. Villiger; Stefano Fontana; Werner J. Pichler; Daniel Yerly

Abacavir hypersensitivity is a severe hypersensitivity reaction which occurs exclusively in carriers of the HLA-B*57∶01 allele. In vitro culture of PBMC with abacavir results in the outgrowth of abacavir-reacting CD8+ T cells, which release IFNγ and are cytotoxic. How this immune response is induced and what is recognized by these T cells is still a matter of debate. We analyzed the conditions required to develop an abacavir-dependent T cell response in vitro. The abacavir reactivity was independent of co-stimulatory signals, as neither DC maturation nor release of inflammatory cytokines were observed upon abacavir exposure. Abacavir induced T cells arose in the absence of professional APC and stemmed from naïve and memory compartments. These features are reminiscent of allo-reactivity. Screening for allo-reactivity revealed that about 5% of generated T cell clones (n = 136) from three donors were allo-reactive exclusively to the related HLA-B*58∶01. The addition of peptides which can bind to the HLA-B*57∶01-abacavir complex and to HLA-B*58∶01 during the induction phase increased the proportion of HLA-B*58∶01 allo-reactive T cell clones from 5% to 42%. In conclusion, abacavir can alter the HLA-B*57∶01-peptide complex in a way that mimics an allo-allele (‘altered self-allele’) and create the potential for robust T cell responses.


American Journal of Pathology | 2014

T Cells Infiltrate the Liver and Kill Hepatocytes in HLA-B∗57:01-Associated Floxacillin-Induced Liver Injury

Natascha Andrea Wuillemin; Luigi Terracciano; Helmut Beltraminelli; Christoph Schlapbach; Stefano Fontana; Stephan Krähenbühl; Werner J. Pichler; Daniel Yerly

Drug-induced liver injury is a major safety issue. It can cause severe disease and is a common cause of the withdrawal of drugs from the pharmaceutical market. Recent studies have identified the HLA-B(∗)57:01 allele as a risk factor for floxacillin (FLUX)-induced liver injury and have suggested a role for cytotoxic CD8(+) T cells in the pathomechanism of liver injury caused by FLUX. This study aimed to confirm the importance of FLUX-reacting cytotoxic lymphocytes in the pathomechanism of liver injury and to dissect the involved mechanisms of cytotoxicity. IHC staining of a liver biopsy from a patient with FLUX-induced liver injury revealed periportal inflammation and the infiltration of cytotoxic CD3(+) CD8(+) lymphocytes into the liver. The infiltration of cytotoxic lymphocytes into the liver of a patient with FLUX-induced liver injury demonstrates the importance of FLUX-reacting T cells in the underlying pathomechanism. Cytotoxicity of FLUX-reacting T cells from 10 HLA-B(∗)57:01(+) healthy donors toward autologous target cells and HLA-B(∗)57:01-transduced hepatocytes was analyzed in vitro. Cytotoxicity of FLUX-reacting T cells was concentration dependent and required concentrations in the range of peak serum levels after FLUX administration. Killing of target cells was mediated by different cytotoxic mechanisms. Our findings emphasize the role of the adaptive immune system and especially of activated drug-reacting T cells in human leukocyte antigen-associated, drug-induced liver injury.


Transfusion | 2006

Prospective, paired crossover comparison of multiple, single-needle plateletpheresis procedures with the Amicus and Trima Accel cell separators.

Stefano Fontana; Livio Mordasini; Peter Keller; Behrouz Mansouri Taleghani

BACKGROUND: The Baxter Amicus Version 2.51 (A) and the Gambro BCT Trima Accel Version 5.0 (T) cell separators may produce multiple platelet (PLT) concentrates within a single donation.


Transfusion | 2010

Efficacy of individual nucleic acid amplification testing in reducing the risk of transfusion-transmitted hepatitis B virus infection in Switzerland, a low-endemic region

Martin Stolz; Caroline Tinguely; Mauro Graziani; Stefano Fontana; Peter Gowland; Andreas Buser; Martine Michel; Giorgia Canellini; Max Züger; Philippe Schumacher; Nico Lelie; Christoph Niederhauser

BACKGROUND: The risk of transfusion‐transmitted hepatitis B virus (HBV) in Switzerland by testing blood donors for hepatitis B surface antigen (HBsAg) alone has been historically estimated at 1:160,000 transfusions. The Swiss health authorities decided not to introduce mandatory antibody to hepatitis B core antigen (anti‐HBc) testing but to evaluate the investigation of HBV nucleic acid testing (NAT).

Collaboration


Dive into the Stefano Fontana's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Werner J. Pichler

University Hospital of Bern

View shared research outputs
Top Co-Authors

Avatar

Jacqueline Adam

University Hospital of Bern

View shared research outputs
Top Co-Authors

Avatar

Kurt Leibundgut

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Klara Eriksson

University Hospital of Bern

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge